Wolverine Asset Management’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-23,593
Closed -$347 1823
2026
Q1
$347 Buy
23,593
+1,300
+6% +$56 ﹤0.01% 1628
2025
Q4
$1.58K Buy
22,293
+515
+2% +$51 ﹤0.01% 1550
2025
Q3
$1.55K Hold
21,778
﹤0.01% 1485
2025
Q2
$1.85K Buy
21,778
+1,500
+7% +$121 ﹤0.01% 1484
2025
Q1
$1.43K Buy
20,278
+15,088
+291% +$2.63K ﹤0.01% 1442
2024
Q4
$664 Sell
5,190
-10,202
-66% -$634 ﹤0.01% 1532
2024
Q3
$692 Buy
15,392
+500
+3% +$37 ﹤0.01% 1547
2024
Q2
$895 Buy
14,892
+12,735
+590% +$1.6K ﹤0.01% 1546
2024
Q1
$404 Sell
2,157
-5,500
-72% -$808 ﹤0.01% 1575
2023
Q4
$993 Sell
7,657
-4,769
-38% -$460 ﹤0.01% 1611
2023
Q3
$995 Buy
+12,426
New +$1.96K ﹤0.01% 1702

Wolverine Asset Management's NRXPW Position: Q2 2026 in Review

Wolverine Asset Management sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q2 2026, closing a stake of 23,593 shares — an estimated $347 sold.

Wolverine Asset Management first reported a position in NRXPW in Q3 2023 and held it in 11 quarters. The position peaked at $1.85K in Q2 2025. 0 funds tracked by Wall St. Rank hold NRXPW as of Q2 2026.

  • Wolverine Asset Management reported no remaining NRX Pharmaceuticals Warrant position as of Q2 2026 after selling out during the quarter.
  • Wolverine Asset Management sold 23,593 NRX Pharmaceuticals Warrant shares in Q2 2026, an estimated $347.
  • Wolverine Asset Management first reported a position in NRX Pharmaceuticals Warrant in Q3 2023 and held it in 11 quarters.
  • Wolverine Asset Management's NRX Pharmaceuticals Warrant position peaked at $1.85K in Q2 2025.
  • 0 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.